NVAX is looking to complete its correction wave pattern. Its holding above its moving averages at the top of the flagging range. It is close to the apex of the range looking to breakout. Looking this to run to 250 area.
Forming a pennant on daily chart. Johnson &Johnson's misfortune still wasn't enough to push through. Channel resistance intersects with fib resistance at 204.
Public info says vaccine approval expected for UK and US use this quarter.
Entry 204 or pennant break out
targets (Green lines) are fib resistance
Price has been respecting the daily uptrend on this pennant pattern formed on the daily time frame. The pattern its formed suggest a break out will likely follow. With the president trying to get everyone vaccinated as soon as possible im bullish on the catalyst. The daily RSI is in a neutral position, and the stochastic looks to be shifting towards the upside. On...
After a 20% drop this morning the stock staged quiet a nice recovery after hitting multiple supports=
- The Fibonacci Golden pocket
- The ascending trendline
- The 100MA.
resulting in a 10% reversal trade.
Lets see what Fridays brings and the possibility for a bounce in the Nasdaq and Biotech sector.
NVAX pulled back, found a large gap, filled it and appears to want to move upward.
Possible stop below C or last pivot low
Possible Targets 2 432.5 to 500
Not a recommendation.
Can be volatile
NVAX pulled back, found a large gap, filled it and appears to want to move upward.
Possible stop below C or last pivot low
Possible Targets 2 432.5 to 500
Not a recommendation.
Can be volatile
NVAX gapped down today right into its moving average support. I believe its going to finish its rounding pattern and exceed the highs from yesterday. The 50 sma is at support as well at the 201 mark. I was able to enter at 214, but couldn't post this idea right away. Target is at the top of rounding formation at 245
Broke above 217.88 (yellow line) heavy resistance premarket.
Good news has been coming out of this company as far as vaccine trials.
American FDA approval could come around may and with that AstraZeneca nightmare in Germany, early Europe approval could be in play.
stop loss at 217
Targets are Fibonacci (Greenlines)
NVAX could not even break and retest the old Resistance from August, it also formed a nice setup, where the break was also a break of the downtrendline at the same time.
Todays Session retested both, now forming a double support, which could allow us some decent gains...
NVAX jumped roughly 20% overnight after announcing 96.4% efficacy against the disease caused by the original COVID-19 strain. This single move caused the shares to break out from the downside channel and crack through the 50-day and 20-day moving averages. With this important resistance zone left behind, the shares are poised to open just above the yearly...
The final analysis of the U.K. trial showed that the vaccine was 96.4% effective against "mild, moderate, and severe disease caused by the original COVID-19 strain.
Vaccine efficacy was 86.3% against the fast-spreading U.K. variant (B.1.1.7/501Y.V1). Overall vaccine efficacy was 89.7%.
Tribune News Service
New Delhi, March 10
India’s indigenous COVID-19 vaccine COVAXIN is no longer to be used in clinical trial mode and has got the nod of national experts to be used under the normal restricted emergency use authorisation route, just like the Serum Institute manufactured Covishield.
The move entails a huge boost to the indigenous Covid vaccine...
After liquidating my 175 puts yesterday, as described in the linked idea,
I am shorting it again via 3/12 120 puts. My bet will win if it has another run down next week.
As a reminder, I don't do Yolo's, so my strategy assumes that I am going to be wrong and lose money most of the time.
I am careful with the size of my bets and this one is no exception.
